

Severe Stroke Clinical Study To Begin Patient Recruitment

Trial to study patients with severe ischemic stroke who are likely to experience clinically significant brain swelling.

New York, NY, USA – April 23, 2011 – Remedy Pharmaceuticals, Inc. today announced that the GAMES-PILOT study of RP-1127 in severe stroke will begin recruiting patients on May 1, 2011.

GAMES-PILOT is a multi-center, prospective, open label, Phase 2a trial of RP-1127 in patients with a severe ischemic stroke who are likely to experience clinically significant brain swelling, termed malignant infarction. Malignant infarction is the syndrome of a large stroke causing progressive edema and tissue swelling that compromises arterial inflow to surrounding tissues, culminating in further ischemic damage, enlargement of the infarct, herniation, and death.

The study will initially enroll at the University of Maryland Medical Center. More centers are expected to be added in the coming months. It is anticipated that the information gained in GAMES-PILOT will allow a much needed, randomized, double-blinded study to be designed for this patient population.

The study's Principal Investigator is Kevin N. Sheth, MD. Dr. Sheth is an Assistant Professor in the departments of neurology, neurosurgery, and anesthesia at the University of Maryland and R. Adams Cowley Shock Trauma. Dr. Sheth completed his fellowship in neuro-critical care at the Harvard Combined Program in Neuro-Critical Care. Dr. Sheth has spoken internationally on cerebral edema and acute brain injury and serves as a reviewer for several prestigious journals including Neurology, Neurosurgery Stroke, and The New England Journal of Medicine.

"There are currently no approved pharmaceutical therapies for malignant infarction. Without therapy, up to 80% of these patients will die from brain herniation or require decompressive surgery to relieve brain swelling," says Sven Jacobson, Chief Executive Officer of Remedy. "RP-1127 specifically targets what appears to be the primary mechanism that leads to brain swelling, and thus may be able to significantly improve outcomes in these large strokes."

Detailed information for this study is available at:
<http://clinicaltrials.gov/ct2/show/NCT01268683>

About RP-1127

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca-ATP} channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com